Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 12 results for "daiichi sankyo"

Daiichi Sankyo settles U.S. lawsuits over blood pressure drug ...

NEW YORK (Reuters) - Daiichi Sankyo on Tuesday said it has agreed to pay up to $300 million to settle some 2,300 U.S. cases accusing the Japanese drugmaker of failing to warn that its blood pressure medication Benicar can cause gastrointestinal illness. Reuters, 2 months ago

Nikkei climbs to 2-week highs as U.S. data bolsters dollar-yen

* Daiichi Sankyo soars after report of rebuffed AstraZenecaoffer * Nikkei volatility index down from highs but market stillwary * U.S. political woes keep investors cautious - analyst By Lisa Twaronite and Ayai Tomisawa TOKYO, Aug 31 (Reuters) - Japan's ...
 Sify1 month ago

Japan's Daiichi Sankyo denies 2016 takeover bid by AstraZeneca

Japanese drugmaker Daiichi Sankyo denied on Thursday it received a takeover bid last year from Britain's AstraZeneca, following speculation that sent its share price soaring as much as 13 percent and triggered a trade suspension. The online version of the ...
 Reuters1 month ago

Bristol-Myers, Daiichi Sankyo to test Opdivo combo for cancers

Bristol-Myers Squibb Co and Daiichi Sankyo said they were evaluating a combination of Bristol-Myers' immuno-oncology drug, Opdivo, with the Japanese company's experimental drug in patients with breast and bladder cancers. Opdivo belongs to a new class of ...
 Reuters1 month ago

Singh brothers' stake halves to 25.3% in Religare Enterprises

The shareholding of the promoters of financial services firm Religare Enterprises has halved to 25.33 per cent in the last quarter. The fall in holding of billionaire brothers Malvinder Mohan Singh and Shivinder Mohan Singh and entities they control, reported ...
 Business Standard6 days ago

Escalating Geo-political Tensions, Rising Gold Prices & Other Top Cues in Action Today

Posted by Equitymaster Indian stock markets ended the previous session lower amidst rising geopolitical tensions. The BSE Sensex closed lower by 190 points while the NSE Nifty finished lower by 62 points. All BSE sectoral indices ended the day in negative ...
 Equitymaster.com1 month ago Sensex Ends 190 Points Lower; Adani Ports & Bharti Airtel Top Losers  Equitymaster.com1 month ago Recovery of Global Markets, Apex Frozen Food IPO & Cues to Watch Out Today  Equitymaster.com1 month ago

Lupin launches generic hypertension drug in US market

Drug maker Lupin today announced the launch of its Olmesartan Medoxomil tablets, a hypertension drug, in the US market. The company has launched the tablets in strengths of 5 mg, 20 mg and 40 mg after having received an approval from the United States Food ...
 Business Standard1 month ago

Supreme Court refuses permission to sell shares in Fortis Healthcare

Shares of Fortis Healthcare closed 5.44 percent lower to trade at Rs 146 per share on Thursday after the Supreme Court refused to afford any relief to promoters Malvinder Singh and Shivinder Sing and lender banks of the company to part with their encumbered ...
 Business Standard1 month ago

UPDATE 1-UK Stocks-Factors to watch on Aug 31

(Adds company news items and futures) Aug 31 (Reuters) - Britain's FTSE 100 index is seen opening up 14points on Thursday, according to financial bookmakers, with futures up0.2 percent ahead of the cash market open. * ASTRAZENECA: Britain's AstraZeneca ...
 Sify1 month ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less